RenovoRx’s TAMP Platform Will Deliver Imugene’s CF33 Oncolytic Virotherapy in Companies’ Research Collaboration

July 20, 2023—RenovoRx, Inc., a Los Altos, California-based clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Limited, a clinical-stage immuno-oncology company headquartered in Sydney, Australia, announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s transarterial microperfusion (TAMP) therapy platform for the treatment of difficult-to-access tumors.

As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform.

The press release noted that CF33 oncolytic virotherapy is aimed at treating a variety of cancers in combination with standard-of-care drugs and emerging immunotherapies such as chimeric antigen receptor T-cells—CAR T—therapy for solid tumors.

According to the companies, the ability to treat difficult-to-access tumors, such as pancreatic and liver cancers, by delivering CF33 transarterially may be valuable to cancer patients compared to traditional administration methods where dense fibrous tissue and lack of blood vessels supplying the tumors have been shown to limit therapy uptake.

The TAMP platform is designed to ensure precise therapeutic delivery to a target tissue with the potential to increase an oncology therapy’s efficacy, improve safety, and widen its therapeutic window by focusing its distribution uniformly in target tissue.

RenovoRx advised that a study presented at the Society of Interventional Radiology’s 2019 annual meeting demonstrated that the TAMP platform resulted in a 100-fold increase in local tissue concentration compared to conventional intravenous delivery as well as advantages compared to off-the-shelf intra-arterial delivery.